Search in the Abstract Database

Search Abstracts 2011

* = Presenting author

P247. Iron status and treatment of iron deficiency with ferric carboxymaltose in IBD patients: A retrospective, single center analysis

F. Beigel, B. Löhr, F. Schnitzler, S. Breiteneicher, M. Weidinger, B. Göke, J. Seiderer, T. Ochsenkühn, S. Brand

Klinikum Grosshadern, LMU Munich, Munich, Germany

Aim: Iron deficiency and iron deficiency anemia are common in patients with inflammatory bowel disease (IBD). Past treatment strategies included mainly oral iron administration with limited efficacy and tolerability. Intravenous iron supplementation is more effective but there are differences in intravenous iron formulations regarding potency, practicability and tolerability. In this study, we analysed iron deficiency and therapeutic response following intravenous iron therapy with ferric carboxymaltose in large single center cohort of IBD patients.

Materials and Methods: Two hundred fifty IBD patients were retrospectively analysed for iron deficiency and iron deficiency anemia. In addition, a subgroup of eighty patients was analysed regarding efficacy and side effects of iron supplementation with ferric carboxymaltose (ferinject®).

Results: In our cohort, 136 patients (54.4%) had iron values ≤60 μg/dL; 201 patients (80.7%) had ferritin levels ≤100 ng/mL, 62 patients (24.8%) were anemic with haemoglobin (Hb) levels ≤12 g/dL (females) or ≤13 g/dL (males) and 61 patients (24.4%) had haematocrit levels ≤36/39. Before the start of ferric carboxymaltose treatment, 83.1% of the patients had serum iron levels ≤ 60 μg/dl, 90.4% had serum ferritin ≤100 ng/ml and 66.7% had Hb levels ≤12/13 g/dL. After a median dose of 500 mg ferric carboxymaltose, 74.7% of the patients reached serum iron values of >60 μg/dl, 61.6% had serum ferritin >100 ng/ml and 90.7% reached Hb levels >12/13 g/dL at follow-up (p < 0.0001 for all parameters vs. pretreatment values). Overall, 13.5% of the patients developed side effects associated with ferric carboxymaltose treatment. The most frequent adverse event was an increase of liver enzymes, which occurred in 7 patients (8.8%) but resolved completely at follow-up. Among the more rare side effects were headaches (n = 1; 1.25%) and feet edema (n = 1; 1.25%).

Conclusion: Iron deficiency and anemia is frequent in IBD patients. Treatment with ferric carboxymaltose for iron deficiency and iron deficiency anemia in IBD patients is very efficious, safe and well tolerated.